Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

67.62 +0.42 (+0.63%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc ADR

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
59 60 Next >
Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028
Palm Beach, FL –– October 12, 2022 – FinancialNewsMedia.com News Commentary – The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth in several worldwide... 
Via FinancialNewsMedia
Exposures COVID-19
Is Seagen Stock a Buy Now?
It's growing faster than competitors, but headwinds might soon bog it down. 
Via The Motley Fool
Alexion aims to advance NMOSD treatment landscape with exceptional ULTOMIRIS® (ravulizumab-cwvz) efficacy data at ECTRIMS 2022
From Alexion
Via Business Wire
PhaseBio Might Have To Return Global Rights To Its Lead Program
Via Benzinga
Japan Approves AstraZeneca's Two Treatments For Asthma, Rare Form Of Cancer
Via Benzinga
AstraZeneca's Asthma Treatment Scores European Approval
Via Benzinga
Illumina Inks AI Pact With AstraZeneca To Accelerate Drug Target Discovery
Via Benzinga
Twitter May Drop Clickable Hashtags, AstraZeneca's Nasal COVID-19 Vaccine Fails Trial, Coinbase Gets Singapore Nod: Top Stories Tuesday, Oct. 11
Reuters US-China Chip War: KLA Relaxes Chip Supply To China 
Via Benzinga
AstraZeneca-Oxford University Partnered Nasal COVID-19 Vaccine Flunks Human Trial
AstraZeneca Plc (NASDAQ: AZN) and Oxford University scientists said that the initial testing of its nasal COVID-19 vaccine did not yield the desired protection. 
Via Benzinga
Have $2,000? 2 Market Crash-Ready Stocks to Buy
These two big pharma stocks have what it takes to bounce back. 
Via The Motley Fool
AstraZeneca's COVID-19 Antibody Treatment Scores Approval In Europe
Via Benzinga
2 Healthcare Stocks That Could Help Make You a Fortune
If given enough time, these two stocks can do the heavy lifting in building wealth for you. 
Via The Motley Fool
Is Illumina Still the Gamechanger in Genomics Sequencing?
Genome sequencing solutions company Illumina (NASDAQ: ILMN) stock has fallen under its pandemic lows. A surprise earnings miss, and lowered guidance has caused 
Via MarketBeat
Topics Earnings Economy Lawsuit
Exposures Financial Legal Supply Chain
Large Cap Biopharmaceuticals: Core Holdings For Your Portfolio
Now that some clarity is apparent for drug pricing legislation you should have a few large-cap biopharmaceutical stocks in your portfolio. 
Via Talk Markets
Will Chart Analysts Notice Bad Omen on AstraZeneca's Chart
If history is any guide, there may be trouble ahead for shares of AstraZeneca (NASDAQ:AZN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the... 
Via Benzinga
Why Is LogicBio (LOGC) Stock Up 600% Today?
LogicBio (LOGC) stock is seeing massive gains on Monday following news that AstraZeneca (AZN) subsidiary Alexion is acquiring the company. 
Via InvestorPlace
Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis
Vaccines that boost the body’s immune system against foreign proteins are different than those that are an inverse vaccine fighting an autoimmune disease. 
Via Benzinga
Why LogicBio Therapeutics Stock Is Soaring Today
LogicBio Therapeutics Inc (NASDAQ: LOGC) shares are trading higher Monday after the company announced it will be acquired by AstraZeneca PLC (NASDAQ: AZN) subsidiary Alexion for $2.07 per share.  
Via Benzinga
Why Are LogicBio Therapeutics Shares Skyrocketing Today?
Via Benzinga
Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine
From Alexion
Via Business Wire
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the... 
Via Benzinga
7 Large-Cap Stocks With Sustained Dividend Growth Potential
Large-cap stocks with dividend growth potential have robust cash flows and are likely to increase their dividends in the coming years. 
Via InvestorPlace
7 Vaccine Stocks to Sell ASAP Now That the ‘Pandemic’s Over’
Investors have seven widely-followed vaccine stocks to sell now, after the world decided the pandemic is over. 
Via InvestorPlace
US Stock Futures Rise Ahead Of Economic Reports, Fed Speakers; Crude Oil Rises 1%
Pre-open movers U.S. stock futures traded higher in early pre-market trade on Tuesday after recording losses on Monday. The Dow Jones fell into a bear market on Monday, while the S&P 500 recorded a... 
Via Benzinga
Burberry Finance Chief Joins GSK As First Woman CFO
Via Benzinga
European Stocks Are Left In Shambles From Russia-Ukraine War: It May Be Time To Buy These 2 High Yielders
As the SPDR Portfolio Europe ETF (ARCA: SPEU) is down roughly 32% year-to-date, it may be a prime moment to hunt for stocks that have become undervalued in the European stock market. The SPDR Portfolio... 
Via Benzinga
3 Medical Stocks Displaying Remarkable Relative Strength In 2022
3 medical stocks that displayed a substantial amount of relative strength year-to-date. 
Via Talk Markets
Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test
Though successful in early testing, it wasn't enough to win a Phase 3 study. 
Via Investor's Business Daily
AstraZeneca Pulls Plug On Ionis Pharma-Partnered Cholesterol Med
Via Benzinga
With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma
Via Benzinga
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
59 60 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.